- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940153
Development and Validation of an AI-Driven Motor Skill Assessment System for Children (AIMAS)
Developing an AI-Driven Motor Skill Assessment System for School Children and Children With Developmental Delay
This study aims to develop and validate the AI-Integrated Motor Assessment System (AIMAS) for evaluating motor skills in children aged 6 to 12 years. The study will include typically developing children and children with developmental delay or motor-related developmental disorders.
Participants will complete standardized gross and fine motor tasks while their movements are video-recorded for AI-based analysis. Some participants will also complete a standardized clinical motor assessment for comparison.
The study will evaluate the reliability, validity, and accuracy of AIMAS, including its ability to identify children with motor difficulties. The long-term goal is to establish AIMAS as an accessible and efficient screening tool that can support earlier referral for further professional assessment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This three-year study will develop and validate the AI-Integrated Motor Assessment System (AIMAS), an AI-based platform that uses video-recorded motor tasks and pose-estimation analysis to assess children's motor performance.
In Year 1, the study will expand the motion dataset, train the AI model, and evaluate reliability and validity. In Year 2, the model will be tested in a new population using measures including ROC curves, AUC, sensitivity, and specificity, and a motor developmental delay risk score will be developed. In Year 3, AIMAS will be evaluated in clinical and educational settings for feasibility, accuracy, and agreement with professional motor assessments.
Approximately 470 children aged 6 to 12 years will be enrolled, including typically developing children and children with developmental delay or motor-related developmental disorders. Participants will complete a one-time assessment involving gross and fine motor tasks, with video recordings collected for AI analysis. A subset will also complete a standardized motor assessment, such as the Bruininks-Oseretsky Test of Motor Proficiency, for criterion-related validation.
The overall goal is to establish AIMAS as a reliable, valid, and scalable screening tool for early identification of motor difficulties in children.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Chia-Ling Chen
- Phone Number: 8148 +883-3-3281200
- Email: clingchen@gmail.com
Study Locations
-
-
Taoyuan City
-
Taoyuan, Taoyuan City, Taiwan, 333
- Recruiting
- Linkou Chang Gung Memorial Hospital
-
Contact:
- Chia-Ling Chen
- Phone Number: 8148 +883-3-3281200
- Email: clingchen@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population will include children aged 6 to 12 years recruited from collaborating hospital outpatient clinics and elementary schools. Participants will include typically developing children and children with developmental delay or motor-related developmental disorders, such as developmental coordination disorder, developmental delay, intellectual disability, mild cerebral palsy, autism spectrum disorder, or other clinician-confirmed developmental motor disorders.
Description
Inclusion Criteria:
Developmental Delay With Motor Disorder Group:
- Children aged 6 to 12 years.
- Able to understand and follow the motor instructions required for the study.
- Clinical diagnosis of developmental delay with motor disorder, such as developmental coordination disorder, developmental delay, intellectual disability, mild cerebral palsy, autism spectrum disorder, or another clinician-confirmed developmental motor disorder.
Typically Developing Group:
- Children aged 6 to 12 years.
- Able to understand and follow the motor instructions required for the study.
- Typical developmental milestones with no history of developmental delay or diagnosed developmental disorder.
Exclusion Criteria:
Developmental Delay With Motor Disorder Group:
- Acute illness that makes participation unsuitable.
- Degenerative or progressive neurological disease.
- Unable to safely complete motor tasks because of conditions such as fracture, physical discomfort, or pain.
Typically Developing Group:
- Prior diagnosis of developmental delay, motor impairment, or another condition affecting motor performance.
- Neurological disorder, genetic syndrome, or major congenital or acquired condition that could influence motor ability.
- Possession of a disability certificate or prior professional identification of significant developmental concerns.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Typically Developing Group
Children aged 6 to 12 years with typical development will complete standardized gross and fine motor assessments with video recording for AI-based analysis using the AI-Integrated Motor Assessment System (AIMAS). |
The AI-Integrated Motor Assessment System (AIMAS) is a video-based motor assessment system that uses artificial intelligence and pose-estimation analysis to evaluate gross and fine motor performance in children. Participants complete standardized motor tasks while their movements are video-recorded for AI-based analysis. A subset of participants also completes a standardized clinical motor assessment for validation of AIMAS results. |
|
Developmental Delay With Motor Disorder Group
Children aged 6 to 12 years with developmental delay or motor-related developmental disorders will complete standardized gross and fine motor assessments with video recording for AI-based analysis using AIMAS. |
The AI-Integrated Motor Assessment System (AIMAS) is a video-based motor assessment system that uses artificial intelligence and pose-estimation analysis to evaluate gross and fine motor performance in children. Participants complete standardized motor tasks while their movements are video-recorded for AI-based analysis. A subset of participants also completes a standardized clinical motor assessment for validation of AIMAS results. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic Accuracy of AIMAS for Identifying Motor Developmental Difficulties
Time Frame: Baseline (Day 1)
|
Diagnostic accuracy of the AI-Integrated Motor Assessment System (AIMAS) in distinguishing typically developing children from children with developmental delay or motor-related developmental disorders. Classification performance will be quantified using the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. |
Baseline (Day 1)
|
|
Reliability of AIMAS
Time Frame: Baseline (Day 1) and repeat assessment (Week 1)
|
Reliability of the AI-Integrated Motor Assessment System (AIMAS) will be quantified using intraclass correlation coefficients (ICC) for inter-rater and test-retest reliability. Inter-rater reliability will be determined by comparing AIMAS measurements obtained from independent raters, while test-retest reliability will be assessed using repeated motor assessments of the same participants. Consistency of AI-based joint and pose estimation will also be examined. |
Baseline (Day 1) and repeat assessment (Week 1)
|
|
Criterion Validity of AIMAS
Time Frame: Baseline (Day 1)
|
Criterion-related validity of the AI-Integrated Motor Assessment System (AIMAS) will be examined by comparing AIMAS-derived motor performance scores with scores obtained from a standardized clinical motor assessment, such as the Bruininks-Oseretsky Test of Motor Proficiency (BOT), in a subset of participants. Associations between AIMAS scores and standardized assessment scores will be quantified using correlation coefficients. |
Baseline (Day 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Group Differences in AIMAS-Derived Motor Task Performance
Time Frame: Baseline (Day 1)
|
Motor task performance will be compared between typically developing children and children with developmental delay or motor-related developmental disorders using quantitative measures derived from the AI-Integrated Motor Assessment System (AIMAS). Outcomes will include task completion time (seconds), task performance accuracy (percentage of correctly completed task components), and joint range of motion (degrees), as applicable to the standardized motor tasks. Between-group differences will be analyzed for each prespecified motor performance measure. |
Baseline (Day 1)
|
|
AIMAS-Derived Motor Developmental Delay Risk Score
Time Frame: Baseline (Day 1)
|
A motor developmental delay risk score will be generated using AIMAS-derived movement features and classification model outputs. The score will represent the estimated probability of motor developmental difficulties, ranging from 0 to 1, with higher values indicating greater predicted risk. |
Baseline (Day 1)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Chia-Ling Chen, Chang Gung Memorial Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Neurobehavioral Manifestations
- Neurodevelopmental Disorders
- Brain Damage, Chronic
- Communication Disorders
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Cerebral Palsy
- Learning Disabilities
- Motor Skills Disorders
Other Study ID Numbers
- 202502153A3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.